EDSA · XBRL financial data

Edesa Biotech financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EDSA's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Nov 22, 2021	FY 2022Sep 30, 2022	FY 2023†Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Revenue	329	—	—	—	—	—
Cost of revenue	18	—	—	—	—	—
Research and development	3,329	—	13,335	4,795	2,882	3,669
General and administrative	3,383	—	5,035	4,428	4,133	4,243
Total operating expenses	6,730	—	—	—	—	—
Operating income (loss)	(6,401)	—	(18,371)	(9,223)	(7,015)	(7,912)
Interest income	38	—	—	—	—	—
Income tax expense (benefit)	1	—	1	1	1	1
Net income (loss)	(6,364)	—	(17,549)	(8,374)	(6,170)	(7,186)
Earnings per share, basic USD per share	—	—	—	(2.93)	(1.93)	(1.27)
Weighted average shares, basic thousands of shares	—	—	—	2,859	3,197	5,677

† Share count changed about 1/6 in the period ending 2023-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (EDSA's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Nov 22, 2021	FY 2022Sep 30, 2022	FY 2023†Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	7,214	—	7,091	5,400	1,000	10,800
Prepaid and other current assets	803	—	746	449	367	78
Total current assets	8,104	—	9,092	6,437	1,676	11,513
Property and equipment, net	15	—	13	9	0	—
Right-of-use asset	160	—	18	91	18	0
Total assets	10,762	—	11,576	8,890	3,814	13,531
Total current liabilities	1,530	—	2,141	1,822	1,833	1,079
Lease liability, non-current	94	—	0	20	0	—
Total liabilities	1,654	—	2,184	1,842	1,833	—
Accumulated deficit	(13,133)	—	(44,045)	(52,419)	(58,589)	(65,911)
Total stockholders' equity	6,631	—	9,391	7,049	1,981	12,452
Total liabilities and equity	10,762	—	11,576	8,890	3,814	13,531
Common shares outstanding (cover page) thousands of shares	10,523	13,519	19,353	3,165	3,468	8,334

† Share count changed about 1/6 in the period ending 2023-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (EDSA's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Nov 22, 2021	FY 2022Sep 30, 2022	FY 2023†Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	(6,364)	—	(17,549)	(8,374)	(6,170)	(7,186)
Stock-based compensation	598	—	2,261	1,246	537	730
Depreciation and amortization	—	—	—	183	186	119
Net cash from operating activities	(4,986)	—	(12,279)	(6,636)	(4,890)	(7,322)
Purchases of property and equipment	5	—	6	0	—	—
Net cash from investing activities	19	—	(6)	0	—	—
Proceeds from issuing common stock	4,361	—	0	4,345	729	7,718
Proceeds from issuing equity	4,361	—	—	300	—	—
Net cash from financing activities	7,093	—	11,630	4,830	592	17,031
Net change in cash	—	—	(748)	(1,730)	(4,324)	9,755

† Share count changed about 1/6 in the period ending 2023-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026
X4 Pharmaceuticals	195,095	2,400	(20,788)*	99.1M	9.4 quarters	Q2 FY26 10-QJun 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
Synergy CHC	292	5,493	(2,045)	14.9M	0.1 quarters	Q1 FY26 10-QMar 31, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
Cellectar Biosciences	33,994	not reported	(6,010)*	9.5M	5.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.